Advanced Biomed (NASDAQ:ADVB – Get Free Report) posted its earnings results on Friday. The company reported ($0.38) earnings per share (EPS) for the quarter, Zacks reports.
Advanced Biomed Price Performance
Shares of ADVB opened at $4.40 on Friday. The stock has a market capitalization of $5.98 million, a P/E ratio of 0.91 and a beta of 0.56. Advanced Biomed has a one year low of $3.61 and a one year high of $25.60. The company has a 50-day simple moving average of $5.19.
Wall Street Analyst Weigh In
Separately, Weiss Ratings initiated coverage on Advanced Biomed in a research note on Monday, January 26th. They issued a “sell (e+)” rating for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.
About Advanced Biomed
Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.
Featured Articles
- Five stocks we like better than Advanced Biomed
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
